;PMID: 2479464 ;source_file_1021.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..37] = [t:0..37] ;1)section:[e:43..93] = [t:43..93] ;2)sentence:[e:97..237] = [t:97..237] ;3)section:[e:241..289] = [t:241..289] ;4)section:[e:293..412] = [t:293..412] ;5)sentence:[e:416..929] = [t:416..929] ;6)sentence:[e:930..1096] = [t:930..1096] ;7)sentence:[e:1097..1206] = [t:1097..1206] ;8)sentence:[e:1207..1389] = [t:1207..1389] ;9)sentence:[e:1390..1566] = [t:1390..1566] ;10)sentence:[e:1567..1771] = [t:1567..1771] ;11)sentence:[e:1772..1845] = [t:1772..1845] ;12)sentence:[e:1846..2047] = [t:1846..2047] ;13)sentence:[e:2048..2242] = [t:2048..2242] ;14)section:[e:2246..2290] = [t:2246..2289] ;Sentence Matching Errors ;ERROR_Section end mismatch[e:2246..2290][t:2246..2289] ;Token/POS Errors ;ERROR_Token in entity file but not tree[2289..2290] ] ;section 0 Span:0..37 ;Cancer Res. 1989 Dec 1;49(23):6551-5. (SEC (FRAG (NNP:[0..6] Cancer) (NNP:[7..10] Res) (.:[10..11] .) (CD:[12..16] 1989) (NNP:[17..20] Dec) (CC:[21..26] 1;49-LRB-) (CD:[26..28] 23) (-RRB-:[28..29] -RRB-) (CD:[29..34] :6551) (CD:[34..36] -5) (.:[36..37] .))) ;section 1 Span:43..93 ;Erratum in: Cancer Res 1990 Jan 15;50(2):449. (SEC (FRAG (NNP:[43..50] Erratum) (IN:[51..53] in) (::[53..54] :) (NNP:[60..66] Cancer) (NNP:[67..70] Res) (CD:[71..75] 1990) (NNP:[76..79] Jan) (CC:[80..86] 15;50-LRB-) (CD:[86..87] 2) (-RRB-:[87..88] -RRB-) (.:[88..92] :449) (.:[92..93] .))) ;sentence 2 Span:97..237 ;Lack of evidence for aromatase in human prostatic tissues: effects of ;4-hydroxyandrostenedione and other inhibitors on androgen metabolism. ;[118..127]:cyp450:"aromatase" ;[168..192]:substance:"4-hydroxyandrostenedione" ;[203..213]:substance:"inhibitors" ;[217..225]:substance:"androgen" (SENT (NP-HLN (NP (NP (NN:[97..101] Lack)) (PP (IN:[102..104] of) (NP (NP (NN:[105..113] evidence)) (PP (IN:[114..117] for) (NP (NP (NN:[118..127] aromatase)) (PP-LOC (IN:[128..130] in) (NP (JJ:[131..136] human) (JJ:[137..146] prostatic) (NNS:[147..154] tissues)))))))) (::[154..155] :) (NP (NP (NNS:[156..163] effects)) (PP (IN:[164..166] of) (NP (NP (NN:[168..192] 4-hydroxyandrostenedione)) (CC:[193..196] and) (NP (JJ:[197..202] other) (NNS:[203..213] inhibitors)))) (PP (IN:[214..216] on) (NP (NN:[217..225] androgen) (NN:[226..236] metabolism)))) (.:[236..237] .))) ;section 3 Span:241..289 ;Brodie AM, Son C, King DA, Meyer KM, Inkster SE. (SEC (FRAG (NNP:[241..247] Brodie) (VBP:[248..250] AM) (,:[250..251] ,) (NNP:[252..255] Son) (NNP:[256..257] C) (,:[257..258] ,) (NNP:[259..263] King) (NNP:[264..266] DA) (,:[266..267] ,) (NNP:[268..273] Meyer) (NNP:[274..276] KM) (,:[276..277] ,) (NNP:[278..285] Inkster) (NNP:[286..289] SE.))) ;section 4 Span:293..412 ;Department of Pharmacology and Experimental Therapeutics, School of Medicine, ; University of Maryland, Baltimore 21201. (SEC (FRAG (NNP:[293..303] Department) (IN:[304..306] of) (NNP:[307..319] Pharmacology) (CC:[320..323] and) (NNP:[324..336] Experimental) (NNP:[337..349] Therapeutics) (,:[349..350] ,) (NNP:[351..357] School) (IN:[358..360] of) (NNP:[361..369] Medicine) (,:[369..370] ,) (NNP:[372..382] University) (IN:[383..385] of) (NNP:[386..394] Maryland) (,:[394..395] ,) (NNP:[396..405] Baltimore) (CD:[406..411] 21201) (.:[411..412] .))) ;sentence 5 Span:416..929 ;The effects of 4-hydroxyandrostenedione (4-OHA) and other aromatase ;inhibitors, 10-propargylestr-4-ene-3,17-dione and ;imidazo[1,5-alpha]-3,4,5,6-tetrahydropyrin-6-yl-(4-benzonitrile), as well as ;5 alpha-reductase inhibitors N,N-diethyl-4-methyl-3-oxo-4-aza-5 ;alpha-androstane-17 beta-carboxyamide and ;4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol were investigated in prostatic ;tissue from six patients with benign prostatic hypertrophy and seven ;patients with prostatic cancer, and from normal men at autopsy. ;[431..455]:substance:"4-hydroxyandrostenedione" ;[457..462]:substance:"4-OHA" ;[474..483]:cyp450:"aromatase" ;[484..494]:substance:"inhibitors" ;[497..530]:substance:"10-propargylestr-4-ene-3,17-dione" ;[536..600]:substance:"imidazo[1,5-alpha]-3,4,5,6-tetrahydropyrin-6-yl-(4-benz ;onitrile)" ;[613..631]:substance:"5 alpha-reductase" ;[632..642]:substance:"inhibitors" ;[643..716]:substance:"N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 ;beta-carboxyamide" ;[722..763]:substance:"4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol" (SENT (S (NP-SBJ-1 (NP (DT:[416..419] The) (NNS:[420..427] effects)) (PP (IN:[428..430] of) (NP (NP (NP (NP (NN:[431..455] 4-hydroxyandrostenedione)) (NP (-LRB-:[456..457] -LRB-) (NN:[457..462] 4-OHA) (-RRB-:[462..463] -RRB-))) (CC:[464..467] and) (NP (NP (JJ:[468..473] other) (NN:[474..483] aromatase) (NNS:[484..494] inhibitors)) (,:[494..495] ,) (NP (NN:[497..530] 10-propargylestr-4-ene-3,17-dione) (CC:[531..534] and) (NN:[536..600] imidazo-LSB-1,5-alpha-RSB--3,4,5,6-tetrahydropyrin-6-yl--LRB-4-benzonitrile-RRB-)))) (,:[600..601] ,) (CONJP (RB:[602..604] as) (RB:[605..609] well) (RB:[610..612] as)) (NP (NP (NML (CD:[613..614] 5) (NN:[616..631] alpha-reductase)) (NNS:[632..642] inhibitors)) (NP (NP (NN:[643..677] N,N-diethyl-4-methyl-3-oxo-4-aza-5) (NN:[679..698] alpha-androstane-17) (NN:[699..716] beta-carboxyamide)) (CC:[717..720] and) (NP (NN:[722..763] 4-methyl-3-oxo-4-aza-androsta-5-ene-17-ol))))))) (VP (VBD:[764..768] were) (VP (VBN:[769..781] investigated) (NP-1 (-NONE-:[781..781] *)) (PP-LOC (IN:[782..784] in) (NP (NP (JJ:[785..794] prostatic) (NN:[795..801] tissue)) (PP (PP (IN:[803..807] from) (NP (NP (NP (CD:[808..811] six) (NNS:[812..820] patients)) (PP (IN:[821..825] with) (NP (JJ:[826..832] benign) (JJ:[833..842] prostatic) (NN:[843..854] hypertrophy)))) (CC:[855..858] and) (NP (NP (CD:[859..864] seven) (NNS:[865..873] patients)) (PP (IN:[874..878] with) (NP (JJ:[880..889] prostatic) (NN:[890..896] cancer)))))) (,:[896..897] ,) (CC:[898..901] and) (PP (IN:[902..906] from) (NP (NP (JJ:[907..913] normal) (NNS:[914..917] men)) (PP (IN:[918..920] at) (NP (NN:[921..928] autopsy)))))))))) (.:[928..929] .))) ;sentence 6 Span:930..1096 ;We attempted to measure aromatase activity in the tissue incubations by ;quantitating 3H2O released from androstenedione or testosterone labeled at ;the C-1 position. ;[955..964]:cyp450:"aromatase" ;[1016..1020]:substance:"3H2O" ;[1036..1051]:substance:"androstenedione" ;[1055..1067]:substance:"testosterone" (SENT (S (NP-SBJ-1 (PRP:[930..932] We)) (VP (VBD:[933..942] attempted) (S (NP-SBJ-1 (-NONE-:[942..942] *)) (VP (TO:[943..945] to) (VP (VB:[946..953] measure) (NP (NP (NN:[955..964] aromatase) (NN:[965..973] activity)) (PP-LOC (IN:[974..976] in) (NP (DT:[977..980] the) (NN:[981..987] tissue) (NNS:[988..999] incubations)))) (PP-MNR (IN:[1000..1002] by) (S-NOM (NP-SBJ (-NONE-:[1002..1002] *)) (VP (VBG:[1003..1015] quantitating) (NP (NP (NN:[1016..1020] 3H2O)) (VP (VBN:[1021..1029] released) (NP (-NONE-:[1029..1029] *)) (PP (IN:[1030..1034] from) (NP (NP (NN:[1036..1051] androstenedione) (CC:[1052..1054] or) (NN:[1055..1067] testosterone)) (VP (VBN:[1068..1075] labeled) (NP (-NONE-:[1075..1075] *)) (PP-LOC (IN:[1076..1078] at) (NP (DT:[1079..1082] the) (NN:[1083..1086] C-1) (NN:[1087..1095] position))))))))))))))) (.:[1095..1096] .))) ;sentence 7 Span:1097..1206 ;High performance liquid chromatography and thin layer chromatography were ;used to isolate steroid products. ;[1188..1205]:substance:"steroid products" (SENT (S (NP-SBJ-1 (NP (NML (JJ:[1097..1101] High) (NN:[1102..1113] performance)) (NN:[1115..1121] liquid) (NN:[1122..1136] chromatography)) (CC:[1137..1140] and) (NP (NML (JJ:[1141..1145] thin) (NN:[1146..1151] layer)) (NN:[1152..1166] chromatography))) (VP (VBD:[1167..1171] were) (VP (VBN:[1172..1176] used) (NP-1 (-NONE-:[1176..1176] *)) (S-PRP (NP-SBJ (-NONE-:[1176..1176] *)) (VP (TO:[1177..1179] to) (VP (VB:[1180..1187] isolate) (NP (JJ:[1188..1195] steroid) (NNS:[1197..1205] products))))))) (.:[1205..1206] .))) ;sentence 8 Span:1207..1389 ;Although the amount of 3H2O released was at least twice that of the ;heat-inactivated tissue samples, no estrone or estradiol was detected on high ; performance liquid chromatography. ;[1230..1234]:substance:"3H2O" ;[1312..1319]:substance:"estrone" ;[1323..1332]:substance:"estradiol" (SENT (S (SBAR-ADV (IN:[1207..1215] Although) (S (NP-SBJ (NP (DT:[1216..1219] the) (NN:[1220..1226] amount)) (PP (IN:[1227..1229] of) (NP (NP (NN:[1230..1234] 3H2O)) (VP (VBN:[1235..1243] released) (NP (-NONE-:[1243..1243] *)))))) (VP (VBD:[1244..1247] was) (NP-PRD (NP (QP (IN:[1248..1250] at) (JJS:[1251..1256] least) (RB:[1257..1262] twice)) (DT:[1263..1267] that)) (PP (IN:[1268..1270] of) (NP (DT:[1271..1274] the) (ADJP (NN:[1276..1280] heat) (HYPH:[1280..1281] -) (VBN:[1281..1292] inactivated)) (NN:[1293..1299] tissue) (NNS:[1300..1307] samples))))))) (,:[1307..1308] ,) (NP-SBJ-1 (DT:[1309..1311] no) (NN:[1312..1319] estrone) (CC:[1320..1322] or) (NN:[1323..1332] estradiol)) (VP (VBD:[1333..1336] was) (VP (VBN:[1337..1345] detected) (NP-1 (-NONE-:[1345..1345] *)) (PP (IN:[1346..1348] on) (NP (NML (JJ:[1349..1353] high) (NN:[1355..1366] performance)) (NN:[1367..1373] liquid) (NN:[1374..1388] chromatography))))) (.:[1388..1389] .))) ;sentence 9 Span:1390..1566 ;The 3H2O release was significantly inhibited by 4-OHA and ;N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide, ;but not by the other aromatase inhibitors. ;[1394..1398]:substance:"3H2O" ;[1439..1444]:substance:"4-OHA" ;[1449..1522]:substance:"N,N-diethyl-4-methyl-3-oxo-4-aza-5 ;alpha-androstane-17 beta-carboxyamide" ;[1545..1554]:cyp450:"aromatase" ;[1555..1565]:substance:"inhibitors" (SENT (S (NP-SBJ-1 (DT:[1390..1393] The) (NN:[1394..1398] 3H2O) (NN:[1399..1406] release)) (VP (VBD:[1407..1410] was) (VP (VP (ADVP (RB:[1411..1424] significantly)) (VBN:[1425..1434] inhibited) (NP-1 (-NONE-:[1434..1434] *)) (PP=2 (IN:[1436..1438] by) (NP-LGS (NP (NN:[1439..1444] 4-OHA)) (CC:[1445..1448] and) (NP (NN:[1449..1483] N,N-diethyl-4-methyl-3-oxo-4-aza-5) (NN:[1484..1503] alpha-androstane-17) (NN:[1505..1522] beta-carboxyamide))))) (,:[1522..1523] ,) (CC:[1524..1527] but) (VP (RB:[1528..1531] not) (PP=2 (IN:[1532..1534] by) (NP-LGS (DT:[1535..1538] the) (JJ:[1539..1544] other) (NN:[1545..1554] aromatase) (NNS:[1555..1565] inhibitors)))))) (.:[1565..1566] .))) ;sentence 10 Span:1567..1771 ;4-OHA also inhibited 5 alpha-reductase in both benign prostatic hypertrophy ;and cancer tissue, although to a lesser extent than ;N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxyamide. ;[1567..1572]:substance:"4-OHA" ;[1589..1606]:substance:"5 alpha-reductase" ;[1697..1770]:substance:"N,N-diethyl-4-methyl-3-oxo-4-aza-5 ;alpha-androstane-17 beta-carboxyamide" (SENT (S (NP-SBJ (NN:[1567..1572] 4-OHA)) (ADVP (RB:[1573..1577] also)) (VP (VBD:[1579..1588] inhibited) (NP (CD:[1589..1590] 5) (NN:[1591..1606] alpha-reductase)) (PP-LOC (IN:[1607..1609] in) (NP (DT:[1610..1614] both) (NP (JJ:[1615..1621] benign) (JJ:[1622..1631] prostatic) (NN:[1632..1643] hypertrophy)) (CC:[1644..1647] and) (NP (NN:[1648..1654] cancer) (NN:[1656..1662] tissue)))) (,:[1662..1663] ,) (SBAR-ADV (IN:[1664..1672] although) (FRAG (PP (TO:[1673..1675] to) (NP (NP (DT:[1676..1677] a) (JJR:[1678..1684] lesser) (NN:[1685..1691] extent)) (SBAR (IN:[1692..1696] than) (S (NP-SBJ (NN:[1697..1731] N,N-diethyl-4-methyl-3-oxo-4-aza-5) (NN:[1733..1752] alpha-androstane-17) (NN:[1753..1770] beta-carboxyamide)) (VP (-NONE-:[1770..1770] *?*))))))))) (.:[1770..1771] .))) ;sentence 11 Span:1772..1845 ;The other aromatase inhibitors were without effect on 5 alpha-reductase. ;[1782..1791]:cyp450:"aromatase" ;[1792..1802]:substance:"inhibitors" ;[1827..1844]:substance:"5 alpha-reductase" (SENT (S (NP-SBJ (DT:[1772..1775] The) (JJ:[1776..1781] other) (NN:[1782..1791] aromatase) (NNS:[1792..1802] inhibitors)) (VP (VBD:[1803..1807] were) (PP-PRD (IN:[1809..1816] without) (NP (NP (NN:[1817..1823] effect)) (PP (IN:[1824..1826] on) (NP (CD:[1827..1828] 5) (NN:[1829..1844] alpha-reductase)))))) (.:[1844..1845] .))) ;sentence 12 Span:1846..2047 ;Our results indicate that 3H2O released from [1 beta-3H]androstenedione and ;[1,2,6,7-3H]androstenedione does not correlate with estrogen formation and ;may be the result of other metabolic reactions. ;[1872..1876]:substance:"3H2O" ;[1892..1918]:substance:"[1 beta-3H]androstenedione" ;[1923..1950]:substance:"[1,2,6,7-3H]androstenedione" ;[1976..1984]:substance:"estrogen" (SENT (S (NP-SBJ (PRP$:[1846..1849] Our) (NNS:[1850..1857] results)) (VP (VBP:[1858..1866] indicate) (SBAR (IN:[1867..1871] that) (S (NP-SBJ (NP (NN:[1872..1876] 3H2O)) (VP (VBN:[1877..1885] released) (NP (-NONE-:[1885..1885] *)) (PP (IN:[1887..1891] from) (NP (NN:[1892..1918] -LSB-1-SP-beta-3H-RSB-androstenedione) (CC:[1919..1922] and) (NN:[1923..1950] -LSB-1,2,6,7-3H-RSB-androstenedione))))) (VP (VP (VBZ:[1951..1955] does) (RB:[1956..1959] not) (VP (VB:[1961..1970] correlate) (PP-CLR (IN:[1971..1975] with) (NP (NN:[1976..1984] estrogen) (NN:[1985..1994] formation))))) (CC:[1995..1998] and) (VP (MD:[1999..2002] may) (VP (VB:[2003..2005] be) (NP-PRD (NP (DT:[2006..2009] the) (NN:[2010..2016] result)) (PP (IN:[2017..2019] of) (NP (JJ:[2020..2025] other) (JJ:[2026..2035] metabolic) (NNS:[2037..2046] reactions)))))))))) (.:[2046..2047] .))) ;sentence 13 Span:2048..2242 ;Although it appears that the prostate lacks aromatase, 4-OHA may be of ;benefit in patients with benign prostatic hypertrophy or prostatic cancer by ;inhibiting this enzyme in peripheral tissue. ;[2092..2101]:cyp450:"aromatase" ;[2103..2108]:substance:"4-OHA" ;[2214..2220]:cyp450:"enzyme" (SENT (S (SBAR-ADV (IN:[2048..2056] Although) (S (S-ADV (PRP:[2057..2059] it)) (VP (VBZ:[2060..2067] appears) (SBAR (IN:[2068..2072] that) (S (NP-SBJ (DT:[2073..2076] the) (NN:[2077..2085] prostate)) (VP (VBZ:[2086..2091] lacks) (NP (NN:[2092..2101] aromatase)))))))) (,:[2101..2102] ,) (NP-SBJ (NN:[2103..2108] 4-OHA)) (VP (MD:[2109..2112] may) (VP (VB:[2113..2115] be) (PP-PRD (IN:[2117..2119] of) (NP (NN:[2120..2127] benefit))) (PP-LOC (IN:[2128..2130] in) (NP (NP (NNS:[2131..2139] patients)) (PP (VBP:[2140..2144] with) (NP (NP (JJ:[2145..2151] benign) (JJ:[2152..2161] prostatic) (NN:[2162..2173] hypertrophy)) (CC:[2174..2176] or) (NP (JJ:[2177..2186] prostatic) (NN:[2187..2193] cancer)))))) (PP (IN:[2194..2196] by) (S-NOM (NP-SBJ (-NONE-:[2196..2196] *)) (VP (VBG:[2198..2208] inhibiting) (NP (DT:[2209..2213] this) (NN:[2214..2220] enzyme)) (PP-LOC (IN:[2221..2223] in) (NP (JJ:[2224..2234] peripheral) (NN:[2235..2241] tissue)))))))) (.:[2241..2242] .))) ;section 14 Span:2246..2289 ;PMID: 2479464 [PubMed - indexed for MEDLINE (SEC (FRAG (NNP:[2246..2250] PMID) (::[2250..2251] :) (CD:[2252..2259] 2479464) (-LRB-:[2260..2261] -LSB-) (NNP:[2261..2267] PubMed) (::[2268..2269] -) (VBN:[2270..2277] indexed) (IN:[2278..2281] for) (NNP:[2282..2289] MEDLINE))) ;ERROR_Orphan Text from EOF Tree File[2289..EOF] ] (ORPH -RSB-)